An open label clinical trial of reboxetine in patients with major depressive disorder

被引：0
|
作者：
Demir, B
Soykan, A
Devrimci-Ozguven, H
Gögüs, A
Haller, T
机构：
[1] Univ Hacettepe, Dept Psychiat, TR-06100 Ankara, Turkey
[2] Ankara Univ, Dept Psychiat, TR-06100 Ankara, Turkey
[3] Pharmacia Canada, CNS, Markham, ON, Canada
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S221 / S221
页数：1
相关论文
共 50 条
  • [1] Effect of reboxetine on major depressive disorder in breast cancer patients: An open-label study
    Grassi, L
    Biancosino, B
    Marmai, L
    Righi, R
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (04) : 515 - 520
  • [2] An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder
    Carvalhal, AS
    de Abreu, PB
    Spode, A
    Correa, J
    Kapczinski, F
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (04) : 421 - 424
  • [3] Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study
    Rapaport, M
    Wilcox, C
    Heiser, J
    Londborg, P
    Schwartz, G
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S205 - S205
  • [4] Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms: An Open-Label Trial
    Golubchik, Pavel
    Sever, Jonathan
    Weizman, Abraham
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (02) : 37 - 41
  • [5] Therapeutic response to reboxetine in patients with major depressive disorder
    Dabrowska, E
    Haller, T
    Bartlett, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S206 - S207
  • [6] A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial
    Yazicioglu, Bengi
    Akkaya, Cengiz
    Sarandol, Asli
    Akgoz, Semra
    Eker, S. Saygin
    Kirli, Selcuk
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1271 - 1276
  • [7] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S375 - S376
  • [8] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S549 - S550
  • [9] Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial
    Kelley, John M.
    Kaptchuk, Ted J.
    Cusin, Cristina
    Lipkin, Samuel
    Fava, Maurizio
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2012, 81 (05) : 312 - 314
  • [10] Comparison of The Efficacy and Safety of Sertraline, Reboxetine, and Venlafaxine in Patients with Major Depressive Disorder: A Pooled Analysis of Four Randomized, Open-Label Trials
    Akkaya, Cengiz
    Kirli, Selcuk
    Eker, Salih Saygin
    Cangur, Sengul
    Canbazoglu, Mustafa
    Sarandol, Asli
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 20 (04): : 274 - 287
12345